tirzepatide weight loss trial results surmount-1 SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes The results are finally in – Today, we reported positive Phase

Study 2: SUSTAIN-6 Trial (Diabetes & Cardiovascular Risk) In the SUSTAIN-6 trial, semaglutide significantly reduced the risk of major cardiovascular events including heart attack and stroke in people with type 2 diabetes

In addition, high levels of B12 and NAD have been correlated with longer telomeres, specialized proteins at the ends of linear chromosomes

Low-Impact Exercise: Activities such as walking, yoga, or swimming combined with microdosing can boost metabolic health

With the education and information our team provides, you will find that losing weight and keeping it off is easier than ever with our team by your side